[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Soviet_Gildong "MindWalk $HYFT There are now three former Aldevron executives at MindWalk and thats something worth paying attention to. Aldevron was acquired by Danaher for $XXX billion and continues to operate as an independent brand. Danaher known for its aggressive M&A strategy has a long history of integrating high-value biotech and life-science companies. If its operations were ever to converge with MindWalks AI-driven platform the synergy could be extraordinary Drop your Opinion"
X Link @Soviet_Gildong 2025-10-21T12:09Z 1545 followers, 1673 engagements

"@mindwalkcorp I signed up for the newsletter and forward to receiving lots of great updates from now on"
X Link @Soviet_Gildong 2025-10-30T13:10Z 1545 followers, XXX engagements

"$HYFT They tapped the heart and I felt a little flutter Thanks marketing team of Mindwalk"
X Link @Soviet_Gildong 2025-10-30T13:46Z 1546 followers, XXX engagements

"MindWalk $HYFT Eli Lilly $LLY has become the first pharmaceutical company to establish an AI factory through its collaboration with NVIDIA $NVDA and this also represents a major opportunity for MindWalk. To put it metaphorically: throughout history winning a war has depended not only on the number of soldiers or the quality of weapons but on the brilliance of the generals who command them. Even when outnumbered great generals have achieved miraculous victories because in economic terms they were extraordinarily efficient resources. MindWalk plays the role of that general. They understand how"
X Link @Soviet_Gildong 2025-10-30T01:23Z 1550 followers, 1386 engagements

"In October 2024 the FDA and EMA discussed ways to simplify the development process for biosimilars during the GRx+Biosims conference and as of 2025 they have begun to put those plans into action. This shift marks a major turning point for the pharmaceutical industry and its particularly unfavorable news for big pharma like $LLY $JNJ $AZN Between 2025 and 2030 approximately XXX blockbuster drugs are set to lose their patents. Once these patents expire biosimilar companies will be able to produce copy versions of those drugs causing major pharmaceutical firms to lose substantial revenue. (The"
X Link @Soviet_Gildong 2025-10-30T01:57Z 1550 followers, 2772 engagements

"In this environment I see tremendous potential in $ABCL and $HYFT. When in-house R&D alone is no longer enough for big pharma its the biotech innovatorsthose capable of dramatically reducing both development time and failure ratesthat will take center stage.Their moment is coming. The current price movements of these companies suggest that momentum is building rapidlyit's only a matter of time before it explodes"
X Link @Soviet_Gildong 2025-10-30T02:06Z 1550 followers, 1913 engagements

"MindWalk $HYFT Something seems off. Since the large-scale buying on October 27th the trading volume has sharply declined and yesterday only about 130K shares were traded. It might have entered a Volume Squeeze Setup. Who knows🤫"
X Link @Soviet_Gildong 2025-10-31T02:15Z 1550 followers, XXX engagements

"The market currently isnt paying much attention to early-stage pure AI drug discovery companies You can see this by looking at $ABCL $HYFT its stock shows a very similar trend. At present AI accounts for less than XX% of the actual drug-discovery process with the rest still relying on traditional methods. AI-designed antibodies tend to have a higher success rate in Phase X trials compared to conventional ones but theres still a serious lack of Phase X clinical data. The market will only start assigning a premium once these AI-designed drugs are validated in late-stage trials. Ultimately its"
X Link @Soviet_Gildong 2025-10-31T02:28Z 1550 followers, 2585 engagements